

being developed to support the identification and care of children with prenatal substance or alcohol exposure in the child welfare system.

**DATES:** *Comments due within 30 days of publication.* The Office of Management and Budget (OMB) must make a decision about the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication.

**ADDRESSES:** Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to [www.reginfo.gov/public/do/PRAMain](http://www.reginfo.gov/public/do/PRAMain). Find this particular information collection by selecting "Currently under 30-day Review—Open for Public Comments" or by using the search function. You can also obtain copies of the proposed collection of information by emailing [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov). Identify all emailed requests by the title of the information collection.

**SUPPLEMENTARY INFORMATION:**

**Description:** The proposed information collection effort will gather data from end users of a toolkit of resources sponsored by the Children's Bureau in collaboration with the Centers for Disease Control and Prevention under an interagency agreement. The toolkit is intended to support child welfare agency staff in the identification and support of children living with prenatal exposure to alcohol and other substances. The data collected will be used in a formative evaluation of the toolkit, which will be guided by three research questions: (1) To what degree do agency staff find toolkit resource to be relevant and applicable to their work?; (2) To what degree do toolkit resources change agency staff attitudes and increase staff knowledge?; (3) What implementation approaches and organizational supports facilitate toolkit use by child welfare agencies? Proposed data sources for this effort include five surveys: (1) a survey to measure users' reactions to the toolkit; (2) a survey of users' attitudes toward Prenatal Alcohol Exposure (PAE)-related issues; (3) a survey of users' knowledge about PAE-related issues; and (4 and 5) two versions of a survey of transfer potential

and perceived competence, which measures users' sense of competence in PAE-related knowledge and skills and the extent to which users believe they will transfer knowledge/skills to their work. One version of this instrument contains the full survey and will be administered after users have been exposed to the full toolkit and its resources. The second version contains a smaller selection of key items from the survey, tailored to collect information from users after their exposure to each of five key modules of the toolkit. All data will be collected over the course of 6–9 months in 2023.

**Respondents:** Child welfare professionals, including state and/or county-level directors of child welfare agencies; supervisors; program staff (e.g., investigation/intake, case management, foster care/adoption/permanency, etc.); staff working in specialist roles that align with toolkit resources (e.g., data/quality improvement specialists); local or state agency managers involved in determining agency strategic plans and practice guidance (e.g., substance-exposed newborn program manager); training system lead staff.

**ANNUAL BURDEN ESTIMATES**

Instrument	Total number of respondents	Total number of responses per respondent	Average burden hours per response	Total/annual burden hours
Survey of reactions to the toolkit .....	32	1	.05	2
Survey of attitudes .....	32	2	.17	11
Survey of PAE-related knowledge .....	32	3	.27	26
Survey of transfer potential and perceived competency .....	32	1	.09	3
Module-specific transfer potential and perceived competency items .....	32	5	.03	5

*Estimated Total Annual Burden Hours:* 47.

**Authority:** Child Abuse Prevention and Treatment Act Reauthorization Act, 42 U.S.C. 5105, (2010).

**John M. Sweet Jr.,**  
ACF/OPRE Certifying Officer.

[FR Doc. 2023–00306 Filed 1–9–23; 8:45 am]

**BILLING CODE 4184–29–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Advisory Council on Alzheimer's Research, Care, and Services; Meeting**

**AGENCY:** Assistant Secretary for Planning and Evaluation, HHS.

**ACTION:** Notice of meeting.

**SUMMARY:** This notice announces the public meeting of the Advisory Council on Alzheimer's Research, Care, and

Services (Advisory Council). The Advisory Council provides advice on how to prevent or reduce the burden of Alzheimer's disease and related dementias (ADRD) on people with the disease and their caregivers. During the meeting on January 30 and 31, 2023, the Advisory Council will hear presentations on issues related to clinical practice and plans for advanced care planning. The second day presentations will review the impact of new drug approvals and focus on risk reduction and social determinants of health. The National Institute of Neurological Disorders and Stroke (NINDS) will present research milestones from the 2022 ADRD summit and other Federal agencies will also provide updates.

**DATES:** The meeting will be held virtually on January 30th from 12:30

p.m. to 4:30 p.m. EST and January 31st from 12:30 p.m. to 4:30 p.m. EST.

**ADDRESSES:** The meeting will be virtual. It will stream live at [www.hhs.gov/live](http://www.hhs.gov/live).

**Comments:** Time is allocated on the agenda to hear public comments from 4:00 p.m. to 4:30 p.m. on Tuesday January 31st. The time for oral comments will be limited to two (2) minutes per individual. In order to provide a public comment, please register by emailing your name to [napa@hhs.gov](mailto:napa@hhs.gov) by Thursday, January 26. Registered commenters will receive both a dial-in number and a link to join the meeting virtually; individuals will have the choice to either join virtually via the link, or to call in only by using the dial-in number. **NOTE:** There may be a 30–45 second delay in the livestream video presentation of the conference. For this reason, if you have pre-registered to submit a public comment, it is

important to connect to the meeting by 3:45 p.m. to ensure that you do not miss your name and allotted time when called. If you miss your name and allotted time to speak, you may not be able to make your public comment. All participant audio lines will be muted for the duration of the meeting and only unmuted by the Host at the time of the participant's public comment. Should you have questions during the session email [napa@hhs.gov](mailto:napa@hhs.gov) and someone will respond to your message as quickly as possible.

In order to ensure accuracy, please submit a written copy of oral comments for the record by emailing [napa@hhs.gov](mailto:napa@hhs.gov) by Wednesday, February 1, 2023. These comments will be shared on the website and reflected in the meeting minutes.

In lieu of oral comments, formal written comments may be submitted for the record by Wednesday, February 1, 2023 to Helen Lamont, Ph.D., OASPE, 200 Independence Avenue SW, Room 424E, Washington, DC 20201. Comments may also be sent to [napa@hhs.gov](mailto:napa@hhs.gov). Those submitting written comments should identify themselves and any relevant organizational affiliations.

**FOR FURTHER INFORMATION CONTACT:**

Helen Lamont, 202–260–6075, [helen.lamont@hhs.gov](mailto:helen.lamont@hhs.gov). Note: The meeting will be available to the public live at [www.hhs.gov/live](http://www.hhs.gov/live).

**SUPPLEMENTARY INFORMATION:** Notice of these meetings is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)). Topics of the Meeting: clinical care, dementia risk reduction, social determinants of health.

**Procedure and Agenda:** The meeting will be webcast at [www.hhs.gov/live](http://www.hhs.gov/live) and video recordings will be added to the National Alzheimer's Project Act website when available, after the meeting.

**Authority:** 42 U.S.C. 11225; Section 2(e)(3) of the National Alzheimer's Project Act. The panel is governed by provisions of Public Law 92–463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees.

Dated: December 23, 2022.

**Benjamin Sommers,**

*Senior Official Performing the Duties of the Assistant Secretary for Planning and Evaluation, Deputy Assistant Secretary for Health Policy.*

[FR Doc. 2023–00290 Filed 1–9–23; 8:45 am]

**BILLING CODE 4150–05–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Office of the Secretary**

**Delegation of Authorities**

Notice is hereby given that I have delegated to the Administrator, Centers for Medicare & Medicaid Services (CMS) with authority to re-delegate the authorities vested in me as the Secretary of Health and Human Services pursuant to the Inflation Reduction Act (IRA, Pub. L. No: 117–169). The authority delegated is delineated in the following IRA provisions Sections 11001–11002: Drug Price Negotiation, 11101: Part B Inflation Rebate, and 11102: Part D Inflation Rebate. This delegation of authority would support the Federal Government's efforts under the IRA to reduce prices for select high-cost drugs under Medicare Parts B and D (sections 11001–11004) and curb drug price increases to below the rate of inflation (sections 11101 and 11102). Without this delegation of authority, CMS would not be able to fully administer, implement, and operate these programs and initiatives consistent with the IRA.

I hereby affirm and ratify any actions taken by the Administrator, CMS, or other CMS officials, which involve the exercise of these authorities prior to the effective date of this delegation.

This delegation of authority is effective immediately.

This delegation of authority may be re-delegated.

This delegation of authority does not impact any other delegations of authority within CMS or in any other Department of Health and Human Services Operating Division or Staff Division.

Dated: January 5, 2023.

**Xavier Becerra,**

*Secretary.*

[FR Doc. 2023–00296 Filed 1–6–23; 4:15 pm]

**BILLING CODE 4150–03–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Office of the Director, National Institutes of Health: Notice of Meeting**

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Advisory Committee to the Deputy Director for Intramural Research, National Institutes of Health.

The meeting will be held as a virtual meeting and is open to the public as

indicated below. Individuals who plan to view the virtual meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be videocast and can be accessed from the National Institutes of Health (NIH) Zoom website <https://nih.zoomgov.com/j/1605463562?pwd=TEgwWE9TNTlqUGg5THFhbDhPWJzUT09>.

**Name of Committee:** Advisory Committee to the Deputy Director for Intramural Research, National Institutes of Health.

**Date:** February 2, 2023.

**Time:** 10:00 a.m. to 4:00 p.m., EST.

**Agenda:** The meeting will include a discussion of recruitment and retention of trainees and barriers thereto.

**Place:** National Institutes of Health, 1 Center Drive, Building 1, Room 160, Bethesda, MD 20892 (Zoom Meeting).

This meeting is a virtual meeting via Zoom and can be accessed at: <https://nih.zoomgov.com/j/1605463562?pwd=TEgwWE9TNTlqUGg5THFhbDhPWJzUT09>.

**Meeting ID:** 160 546 3562

**Passcode:** 448469

**Dial by your location**

+1 669 254 5252 US (San Jose)  
+1 646 828 7666 US (New York)  
+1 551 285 1373 US  
+1 669 216 1590 US (San Jose)

**Join by SIP:** sip: 1605463562@sip.zoomgov.com.

**Join by H.323**

161.199.138.10 (US West)  
161.199.136.10 (US East)  
**Meeting ID:** 160 546 3562  
**Passcode:** 448469

**Contact Person:** Margaret McBurney, Management Analyst, Office of the Deputy Director for Intramural Research, National Institutes of Health, 1 Center Drive, Room 160, Bethesda, MD 20892–0140, (301) 496–1921, [mmcburney@od.nih.gov](mailto:mmcburney@od.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Office of Intramural Research home page: <https://oir.nih.gov/sourcebook>.

Dated: January 4, 2023.

**David W. Freeman,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2023–00217 Filed 1–9–23; 8:45 am]

**BILLING CODE 4140–01–P**